改良DAL-HX83/90方案治疗儿童郎格罕细胞组织细胞增生症24例疗效观察  

Therapeutic effect of modified DAL-HX83/90 protocol in 24 children with Langerhans cell histocytosis

作　　者：王宏胜[1] 李军[1] 马伴吟[1] 高怡瑾[1] 陆凤娟[1] 钱晓文[1] 

机构地区：[1]复旦大学附属儿科医院血液肿瘤科,上海200032

出　　处：《中国小儿血液与肿瘤杂志》2007年第2期60-63,共4页Journal of China Pediatric Blood and Cancer

摘　　要：要：目的 为提高儿童郎格罕细胞组织细胞增生症（LCH）的预后,在复习文献基础上对DAL-HX 83/90方案进行改良并观察其初步疗效.方法 24例患者按DAL-HX 83/90方案分为A、B、C 3组治疗,再按国际组织细胞协会疗效标准进行疗效评价.结果 18例随访7～53个月,诱导6周时有效率：90.9%（20/22）,化疗结束时有效率94.4%（17/18）,复发率22.2%（4/18）,化疗相关不良反应约50%.3例发生明显后遗症.结论 改良DAL-HX 83/90方案初步疗效较好,根据不同组别选用不同化疗强度可减少化疗不良反应,可作为儿童LCH治疗的有效方案之一继续观察.Objective Explore the result of modified DAL-HX 83/90 protocol in childhood Langerhans cell histiocytosis （LCH） in order to improve the treatment result of LCH patients. Methods 24 cases were divided into group A, B or C. The result of treatment was evaluated by the efficacy criteria of International Study Group of the Histocyte Society. Results 18 cases were followed for 7 - 53 months. The effective rate was 90. 9% （20/22） after inauctlon and 94.4% （17/18） when the protocot was finished. Relapse rate was 22. 2% （4/18）. Adverse reaction of chemotherapy was about 50%. 3 eases got evident sequelae. Condusion The primary result of modified DAL-HX 83/90 protocol is rather good. Its relapse rate and adverse effect is low. After further observation, it may be one of the efficient protocols for LCH children.

关 键 词：郎格罕细胞 组织细胞增生症 儿童 治疗 

分 类 号：R725.5[医药卫生—儿科]